The 4 most recent market catalysts affecting $STXS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
Stereotaxis Secures FDA 510(k) Clearance For GenesisX Robotic Magnetic Navigation System
Stereotaxis has secured FDA 510(k) clearance for its GenesisX Robotic Magnetic Navigation System, which is an upgrade to its current Genesis RMN system. This regulatory approval is…
Aug 27, 2026
Corporate Catalyst
Bearish
Impact 55
Citizens Maintains Market Outperform on Stereotaxis, Lowers Price Target to $3
Citizens analyst Daniel Stauder reiterated a 'Market Outperform' rating for Stereotaxis (STXS) but simultaneously lowered the stock's price target from $4 to $3. This action signal…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 75
Stereotaxis Q2 EPS $(0.05) Beats $(0.06) Estimate, Sales $7.670M Miss $8.350M Estimate
Stereotaxis (STXS) announced its Q2 earnings, revealing a beat on EPS but a notable miss on revenue. The company's sales of $7.670 million fell short of the $8.350 million estimate…
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 65
Stereotaxis Files Prospectus Related To Resale Of 108.87M Shares Of Common Stock By Selling Stockholders
Stereotaxis has filed a prospectus to register 108.87 million shares of common stock for resale by existing selling stockholders. This is not a primary offering by Stereotaxis to r…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.